Lumos Announces FebriDx CLIA Waiver Application Submission
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Lumos Diagnostics Holdings Ltd. has submitted its application for a CLIA waiver to the U.S. FDA for its product FebriDx, which helps differentiate between bacterial and non-bacterial infections. The clinical trial data for FebriDx exceeded performance targets, demonstrating high concordance rates between trained and untrained operators. This submission triggers milestone payments from BARDA and a prepayment from PHASE Scientific, significantly expanding Lumos's market opportunity in the U.S. The company expects FDA feedback by the end of the first quarter of the following calendar year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Lumos Diagnostics Holdings Ltd. on 6ix
Earlier from Lumos Diagnostics
- Lumos Signs Binding Term Sheet for A$5M Loan Facility
- Reinstatement to Quotation
- Lumos Signs Pivotal US FebriDx Agreement
- Suspension from Quotation
- Pause in Trading
Later from Lumos Diagnostics
- FY25 Appendix 4E
- LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study
- Lumos secures follow-on PKU contract with Aptatek
- Lumos Secures 100% US Medicare Reimbursement for FebriDx
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics